Protein Summary
Cell surface receptor for PLXNB1, PLXNB2, PLXNB3 and PLXND1 that plays an important role in cell-cell signaling. Plays a role in priming antigen-specific T-cells, promotes differentiation of Th1 T-helper cells, and thereby contributes to adaptive immunity. Promotes phosphorylation of TIMD2. Inhibits angiogenesis. Promotes axon growth cone collapse. Inhibits axonal extension by providing local signals to specify territories inaccessible for growing axons (By similarity). This gene encodes a member of the semaphorin family of soluble and transmembrane proteins. Semaphorins are involved in numerous functions, including axon guidance, morphogenesis, carcinogenesis, and immunomodulation. The encoded protein is a single-pass type I membrane protein containing an immunoglobulin-like C2-type domain, a PSI domain and a sema domain. It inhibits axonal extension by providing local signals to specify territories inaccessible for growing axons. It is an activator of T-cell-mediated immunity and sup ...more
- ENST00000355014
- ENSP00000347117
- ENSG00000196189
- ENST00000368282
- ENSP00000357265
- ENST00000368284
- ENSP00000357267
- ENST00000368285
- ENSP00000357268
- SEMAB
- SEMB
- RP35
- SEMB
- SEMAB
- CORD10
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
PubMedID | 0.74 | ||
protein domain | 0.73 | ||
transcription factor | 0.71 | ||
disease perturbation | 0.62 | ||
biological process | 0.57 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 111.37 (req: < 5)
Gene RIFs: 33 (req: <= 3)
Antibodies: 344 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 111.37 (req: >= 5)
Gene RIFs: 33 (req: > 3)
Antibodies: 344 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 14
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0